ArticleFrontiers in endocrinology2025
Evaluation of conditional survival outcomes in patients with redefined anaplastic thyroid carcinoma.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Conditional survival (CS) offers a more precise assessment of prognosis by continuously updating to reflect the current state. This study aimed to analyze the CS outcome of redefined anaplastic thyroid carcinoma (rATC). Methods: A cohort comprising 1424 patients diagnosed with rATC between 2000 and 2018 was extracted from the Surveillance, Epidemiology, and End Results database and subsequently divided into training and validation sets at a ratio of 3:1. We analyzed the CS prognosis of these patients. A Lasso Cox regression model was employed to determine independent risk factors for long-term survival and to develop a predictive nomogram integrating CS analysis, aiming to provide CS estimates and stratify the risk among rATC patients. Results: The likelihood of achieving 5-year CS escalated from 8% after diagnosis to 44%, 68%, 82%, and 95% after 1, 2, 3, and 4 years of survival, respectively. As patients endured longer, their probability of further years of survival augmented. The Lasso Cox regression analysis identified age, tumor stage, surgery, radiotherapy and chemotherapy as the most influential prognostic factors associated with outcomes. Ultimately, we successfully established a novel CS-nomogram, aiming to provide dynamic survival updates for these patients. Our predictive model can quantify patients' risk and stratify it accordingly. Furthermore, after evaluation, the performance of our predictive model was found to be satisfactory. Conclusion: Utilizing extensive SEER datasets, we devised and validated a CS-nomogram, enabling the prediction of the conditional probability of survival for rATC patients. This facilitates the incorporation of survivorship duration into prognostic assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.